MedPath

Dalfampridine

Generic Name
Dalfampridine
Brand Names
Ampyra, Fampyra, Fampridine Accord
Drug Type
Small Molecule
Chemical Formula
C5H6N2
CAS Number
504-24-5
Unique Ingredient Identifier
BH3B64OKL9

Overview

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

Background

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

Indication

Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).

Associated Conditions

  • Multiple Sclerosis

Clinical Trials

Phase 2
Not yet recruiting
Posted: 2024/09/19
Sponsor:
John Elfar
Phase 2
Not yet recruiting
Posted: 2024/03/27
Sponsor:
John Elfar
Phase 2
Not yet recruiting
Posted: 2024/03/06
Sponsor:
John Elfar

FDA Approved Products

Dalfampridine
Manufacturer:Golden State Medical Supply, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/02/21
NDC:51407-246
Dalfampridine
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:10 mg in 1 1
Approved: 2021/11/18
NDC:63629-9450
DALFAMPRIDINE
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/02/15
NDC:65862-863
AMPYRA
Manufacturer:Acorda Therapeutics, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/03/12
NDC:10144-427
Dalfampridine
Manufacturer:Ascend Laboratories, LLC
Route:ORAL
Strength:10 mg in 1 1
Approved: 2022/06/30
NDC:67877-444

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath